Hyaluronic acid is becoming a platform, not an excipient. See 6 breakthroughs reshaping ophthalmic HA through 2030—cross-linked gels, injectables, and more.
READ MOREArtificial tears hit $2.8B in 2026 at 7.74% CAGR. See which ingredients are winning, how preservative-free is reshaping sourcing, and what B2B buyers plan next.
READ MOREOverview of Sterility Requirements for Ophthalmic Sodium Hyaluronate Sterility, bioburden, and endotoxin are distinct tests. Ophthalmic HA products require SAL 10⁻⁶, with limits varying by application (eye drops, OVDs, IOL coatings). Terminal sterilization methods (gamma, EO, heat) damage HA molecular weight. Therefore, sterility is typically achieved via aseptic processing and 0.22 µm filtration, supported by cleanroom controls and media fills. Raw material bioburden (USP <61>/<62>) should be low. EU GMP Annex 1 mandates a Contamination Control Strategy. Supplier audits should confirm aseptic environment, filter integrity testing, and compendial method validation.
READ MORE
